SCHEMBL19871871

SCHEMBL19871871

COC[C@@H]1CCCN1C(=O)CCCCCOC1OC(CO)C(O)C(O)C1NC(C)=O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.58
▸ LGALS8 O00214 1/20 0.49
▸ LGALS3 P17931 1/20 0.49
▸ LGALS4 P56470 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.41
▸ THRB P10828 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ B4GALT1 P15291 1/20 0.40
▸ CD69 Q07108 1/20 0.39
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ ADAMTS5 Q9UNA0 2/20 0.36
▸ ADAMTS4 O75173 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20016515 0.93 MAPK1 (0.62) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL18929646 0.93 MAPK1 (0.62) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL21902739 0.92 MAPK1 (0.60) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL13813121 0.92 MAPK1 (0.60) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL18627852 0.92 MAPK1 (0.60) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL24646161 0.91 MAPK1 (0.55) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL19062174 0.91 MAPK1 (0.55) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL18627853 0.90 MAPK1 (0.54) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL22226885 0.89 MAPK1 (0.54) MAPK1LGALS8LGALS3LGALS4ALDH1A1
SCHEMBL24517536 0.89 MAPK1 (0.53) MAPK1LGALS8LGALS3LGALS4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683499-B2 Compositions and methods for modulating TTR expression IONIS PHARMACEUTICALS, INC. (US) 2020-06-16 — — US disclosed
US-20180044676-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2018-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044676-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION TTR, GALNT1, GALNT3 MAPK1 4758/4885LGALS8 54/4885LGALS3 48/4885
US-10683499-B2 Compositions and methods for modulating TTR expression TTR, GALNT1, GALNT3 MAPK1 4758/4885LGALS8 54/4885LGALS3 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback